The clinical symptoms of neurodegenerative diseases arise years after the onset of neuronal damage. By the time the patient receives a diagnosis, it might be too late to intervene and modify the advanced pathological state of disease. Researchers are now focusing on preventing and stopping the pathological processes in the brain at an earlier, asymptomatic state.

This conference aims to disseminate cutting-edge findings on preclinical neurodegenerative diseases—including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease. The event will provide a unique platform for specialists to come together across disciplines for an authoritative discussion of the methodological, regulatory, and ethical considerations of research in people at asymptomatic states of neurodegenerative disease.

Posters are invited to supplement the invited oral programme. Please submit abstracts by June 3, 2016.

More information: http://www.preclinicalnddconference.com/